BioSpace News Archive

The published data show that 1 week after MANF treatment, there is an increased release of dopamine, as well as increased dopamine turnover.

Professor Thomas Zeller today presented the 12-month results from Veryan Medical’s MIMICS-2 IDE study.

A press release with fourth quarter and full year 2017 financial results will be issued after market close that day.

Sales in the first nine months of FY2017 decreased 0.6% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to ¥999.4 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

Avita Medical announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 31 December 2017.

A conference call will be held on February 7, 2018 at 8:30 a.m. (ET) to discuss the results.

Dr Malcolm R. Brandon and Mr Grahame Leonard, AM have resigned as directors of the Company with effect from 29 January, 2018.

Innovate Biopharmaceuticals shares will commence trading on Nasdaq with the new ticker INNT and will reflect the 1 for 10 reverse split in trading on Wednesday, January 31, 2018.

Edico Genome today announced the expansion of its commercial leadership team with the appointment of Mike Harkins as vice president of sales and Katherine Atkinson as vice president of business development.

The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.